Related Experiment Videos
Platelet function abnormalities in response to arachidonic acid in the acute phase of myocardial infarction
Abstract:
The aggregation of platelets to arachidonic acid was studied serially in patients admitted to the hospital with suspected acute myocardial infarction (MI) and no history of platelet-altering drug ingestion. Of 17 patients studied within the first 48 hours after MI, 16 had a marked decrease in aggregation, to 0.5 mM arachidonic acid (15 +/- 12% compared with 64 +/- 15% for control subjects, p less than 0.01). The exception was a patient with documented coronary artery spasm who was receiving nifedipine at the time of MI. He had a delayed but normal final percent aggregation. The aggregation response returned to normal at 2 to 4 days and was slightly above normal at 6 to 10 days (change not statistically significant). Thromboxane B2 formation correlated with the response of patients' platelets to arachidonic acid (38 +/- 15 ng in the low responders versus 161 +/- 30 ng/3 X 10(8) platelets/4 min in the normal responders, p less than 0.05). Low responding platelets after washing had normal adenosine diphosphate and adenosine triphosphate contents and aggregated and formed thromboxane B2 normally with arachidonic acid. The plasma of patients with MI was found to inhibit platelet aggregation and thromboxane B2 formation to arachidonic acid.
Insights
Platelet aggregation decreased significantly in patients with acute myocardial infarction (MI). This impaired response, linked to inhibited thromboxane B2 formation, normalized within days, suggesting a transient effect of MI on platelet function.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biochemistry
Background:
- Platelet aggregation is crucial for hemostasis and thrombosis.
- Acute myocardial infarction (MI) can affect various physiological processes, including platelet function.
- Understanding platelet behavior post-MI is vital for managing cardiovascular events.
Purpose of the Study:
- To investigate serial changes in platelet aggregation in response to arachidonic acid in patients with suspected acute myocardial infarction (MI).
- To explore the correlation between platelet aggregation, thromboxane B2 formation, and plasma factors in MI patients.
- To assess the recovery of platelet function following acute MI.
Main Methods:
- Serial assessment of platelet aggregation induced by arachidonic acid in 17 patients within 48 hours of MI.
- Measurement of thromboxane B2 formation in platelets.
- Washing and re-aggregation studies of low-responding platelets.
- Analysis of plasma inhibitory effects on platelet aggregation.
Main Results:
- 16 out of 17 MI patients showed significantly reduced platelet aggregation to arachidonic acid.
- A patient with coronary artery spasm on nifedipine exhibited a delayed but normal aggregation response.
- Platelet aggregation and thromboxane B2 formation normalized within 2-4 days post-MI.
- Patient plasma inhibited platelet aggregation and thromboxane B2 formation, suggesting plasma-derived factors are involved.
Conclusions:
- Acute myocardial infarction is associated with a transient, significant decrease in platelet aggregation response to arachidonic acid.
- The observed inhibition appears to be mediated by plasma factors rather than intrinsic platelet defects.
- Platelet function recovers to normal levels within a few days after the acute event.